How much did Snow v Align Technology Inc payout?
Supernus Pharmaceuticals acquired Sage Therapeutics in a transaction valued at an initial 561 million US dollars in cash, translating to 8.50 US dollars per share. Additionally, the acquisition agreement included contingent value rights worth up to an extra 3.50 US dollars per share, which could push the total potential transaction value to approximately 795 million US dollars if specific commercial sales milestones related to Sage's flagship postpartum depression treatment, Zurzuvae, are successfully achieved in future fiscal years. This targeted biopharmaceutical buyout allowed Supernus to expand its central nervous system therapeutic portfolio significantly.
Related FAQs
Public displays of affection, including kissing, are generally discouraged in Abu Dhabi and are considered culturally sensitive.
Whether you are legally required to take a break during an eight-hour work shift depends entirely on the labor laws of the specific state, country, or jurisdiction where you are employed.
Invitation Homes manages single-family rental properties while enforcing clear tenant lease agreements regarding routine property upkeep and repair responsibilities.
Receiving $3,000 per month in Social Security benefits is considered an excellent and well-above-average retirement income compared to national averages.
Paying a two percent annual management fee to a financial advisor is generally considered quite high and well above standard industry pricing norms.
Determining whether Align Technology (ALGN) represents a buy or sell recommendation involves examining consensus analyst ratings from global healthcare and medical device brokers.
Align Technology operates as a consistently profitable medical device enterprise, reporting robust multi-million-dollar quarterly net incomes, healthy gross margins, and strong free cash flow generation.
Align Technology, Inc. is a fully transparent, publicly traded corporation listed on the Nasdaq Global Select Market under the ticker symbol ALGN.